Rankings
▼
Calendar
BIIB Q2 2025 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena
BIIB
Biogen Inc.
$28B
Q2 2025 Earnings
Healthcare
Drug Manufacturers - General
Income Statement
Revenue
$2.6B
+7.3% YoY
Gross Profit
$1.7B
64.2% margin
Operating Income
$588M
22.2% margin
Net Income
$635M
24.0% margin
EPS (Diluted)
$4.35
QoQ Revenue Growth
+8.8%
Cash Flow
Operating Cash Flow
$161M
Free Cash Flow
$144M
Stock-Based Comp.
$75M
Balance Sheet
Total Assets
$28.3B
Total Liabilities
$10.7B
Stockholders' Equity
$17.6B
Cash & Equivalents
$2.8B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2.6B
$2.5B
+7.3%
Gross Profit
$1.7B
$1.5B
+12.6%
Operating Income
$588M
$367M
+60.5%
Net Income
$635M
$584M
+8.8%
Revenue Segments
MS Product Revenues
$1.1B
42%
TYSABRI product
$455M
17%
Fumarate
$406M
16%
SPINRAZA
$393M
15%
Interferon
$247M
9%
Geographic Segments
UNITED STATES
$941M
50%
Non-US
$938M
50%
← FY 2025
All Quarters
Q3 2025 →